Esophageal cancer linked to osteoporosis drugs
By Gene Emery
BOSTON (Reuters) - Merck’s popular osteoporosis drug Fosamax and other similar drugs may carry a risk for esophageal cancer, a Food and Drug Administration official said on Wednesday.
Diane Wysowski of the FDA’s division of drug risk asessment said researchers should check into potential links between so called bisphosphonate drugs and cancer.
In a letter in Thursday’s New England Journal of Medicine, Wysowski said since the initial marketing of Fosamax, known generically as alendronate, in 1995, the FDA has received 23 reports in which patients developed esophageal tumors.
Typically, two years lapsed between the start of the drug and the development of esophageal cancer. Eight patients died, she reported.
In Europe and Japan, 21 cases involving Fosamax have been logged, with another six instances where Procter & Gamble’s Actonel or risedronate and Didronel or etidronate, and Roche’s Boniva (ibandronate) may have been involved. Six of those people died.
Esophagitis, which is an inflammation of the lining of the tube carrying food to the stomach, is already know to be a side effect of the drugs, which is why patients are instructed to remain upright for at least a half hour after taking them.
In addition, Wysowski said, doctors should avoid prescribing the drugs to people with Barrett’s esophagus, which is a change in the lining that leads to the stomach. It is often found in people with acid reflux disease and itself increases the risk of cancer.
In November the FDA said that clinical trial data showed no overall risk of heart rhythm problems in patients taking bisphosphonates.
However, the FDA also said it was aware of conflicting findings in other studies and was considering whether conducting further studies to investigate the risk were feasible.
The drugs aim to treat bone-weakening osteoporosis by increasing bone mass. An estimated 10 million Americans, mostly women, have osteoporosis.
(Editing by Maggie Fox)
--------------------------------------------------------------------------------------------Related Posts:
WASHINGTON (Reuters) - A review of clinical trial data from four drugmakers shows no overall risk of heart problems in patients taking drugs to treat osteoporosis, the U.S. Food and Drug Administration said on Wednesday. The agency reviewed studies on Merck & Co’s Fosamax, Roche’s Boniva, Novartis AG’s Reclast and Procter and Gamble Co’s Actonel and
Full Post: Studies do not link heart risk to bone drugs: FDA
--------------------------------------------------------------------------------------------
NEW YORK (Reuters Health) - Among premenopausal women taking steroids for lupus, various treatments preserve bone mineral density and “should be considered” for preventing the bone-thinning disease osteoporosis, advise researchers in a report published this month. Lupus, technically known as systemic lupus erythematosus or SLE, is a chronic “autoimmune” disease in which the immune system can
Full Post: Attention to bones important in women with lupus
--------------------------------------------------------------------------------------------
NEW YORK (Reuters Health) - It has been known for a while that injections of a class of anti-osteoporosis drugs might trigger jaw bone decay after certain dental procedures, and now it seems that pill forms of the so-called bisphosphonate medications could have the same side effect. Specifically, a study conducted at the University of Southern
Full Post: Bone strengthening pills linked to jaw bone damage
--------------------------------------------------------------------------------------------
By Will Dunham WASHINGTON (Reuters) - People with the lung ailment chronic obstructive pulmonary disease are more likely to get pneumonia if they use inhaled corticosteroid drugs and doctors should be more cautious in prescribing them, researchers said. People with smoking-related chronic obstructive pulmonary disease, or COPD, who took the drugs for symptoms such as cough, wheezing,
Full Post: Inhaled steroids up pneumonia risk in lung ailment
--------------------------------------------------------------------------------------------
WASHINGTON (Reuters) - U.S. health regulators have approved Novartis’ drug Gleevac to reduce the risk of cancer recurring in patients with a rare type of stomach cancer, Novartis said on Friday. Gleevac is already approved by the Food and Drug Administration to treat gastrointestinal stromal tumor, a severe type of cancer that recurs in as many
Full Post: U.S. OKs Novartis Gleevac to reduce recurring cancer